Published in Philos Trans R Soc Lond B Biol Sci on October 19, 2017
Human oncogenic viruses: nature and discovery. Philos Trans R Soc Lond B Biol Sci (2017) 0.75
Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med (2011) 11.09
Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol (2012) 9.28
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet (2004) 8.09
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med (2015) 7.99
Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol (2003) 7.35
Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol (2008) 6.20
Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med (2009) 5.79
Global burden of human papillomavirus and related diseases. Vaccine (2012) 5.48
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol (2015) 4.84
Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet (2011) 4.70
HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med (2011) 4.69
The human papillomavirus infection in men study: human papillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States. Cancer Epidemiol Biomarkers Prev (2008) 3.93
Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst (2011) 3.92
Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature (1982) 3.82
Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer (2012) 3.35
Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst (2009) 3.19
Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer (2004) 3.03
A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine (2012) 3.03
Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine (2006) 2.78
Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine (2007) 2.64
Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis (2015) 2.48
The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis (1996) 2.21
Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res (Phila) (2013) 2.17
Raising expectations for subunit vaccine. J Infect Dis (2014) 2.04
Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. Br J Cancer (2010) 1.89
Cross-roads in the classification of papillomaviruses. Virology (2013) 1.87
Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med (2012) 1.84
Chapter 12: Prophylactic HPV vaccines: underlying mechanisms. Vaccine (2006) 1.73
Updating the natural history of human papillomavirus and anogenital cancers. Vaccine (2012) 1.65
Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study. Lancet Oncol (2015) 1.56
Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine (2007) 1.53
Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. Proc Natl Acad Sci U S A (2007) 1.53
Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis (2005) 1.51
The influence of virus structure on antibody responses and virus serotype formation. Immunol Today (1996) 1.50
Meeting of the Strategic Advisory Group of Experts on immunization, April 2014 –- conclusions and recommendations. Wkly Epidemiol Rec (2014) 1.50
Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. Gynecol Oncol (2009) 1.49
Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. Br J Cancer (2014) 1.45
Evolving immunosuppressive microenvironment during human cervical carcinogenesis. Mucosal Immunol (2008) 1.44
Human papillomavirus 16-associated cervical intraepithelial neoplasia in humans excludes CD8 T cells from dysplastic epithelium. J Immunol (2010) 1.42
Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer (2014) 1.40
Human papillomavirus vaccines--immune responses. Vaccine (2012) 1.40
Economic evaluation of human papillomavirus vaccination in developed countries. Public Health Genomics (2009) 1.35
Epithelial cell responses to infection with human papillomavirus. Clin Microbiol Rev (2012) 1.33
Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions. Sci Transl Med (2014) 1.21
Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience. Clin Infect Dis (2016) 1.20
Nationwide vaccination: a success story in Taiwan. Vaccine (2000) 1.18
Impact of universal vaccination programmes on the epidemiology of hepatitis B: 10 years of experience in Italy. Vaccine (2003) 1.14
ADXS-HPV: a therapeutic Listeria vaccination targeting cervical cancers expressing the HPV E7 antigen. Hum Vaccin Immunother (2014) 1.08
Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine. Vaccine (2006) 1.08
Role of Human Papillomavirus in Penile Carcinomas Worldwide. Eur Urol (2016) 1.07
Serum antibody response following genital {alpha}9 human papillomavirus infection in young men. J Infect Dis (2011) 1.05
Assessing completeness of perinatal hepatitis B virus infection reporting through comparison of immunization program and surveillance data--United States. MMWR Morb Mortal Wkly Rep (2011) 1.04
Characterising the local immune responses in cervical intraepithelial neoplasia: a cross-sectional and longitudinal analysis. BJOG (2008) 1.01
Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old. Clin Vaccine Immunol (2011) 0.99
Prophylactic vaccination against hepatitis B: achievements, challenges and perspectives. Med Microbiol Immunol (2014) 0.98
Hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine: a review of HEPLISAV™ safety and efficacy. Expert Rev Vaccines (2011) 0.95
Immunogenicity and Safety of a 9-Valent HPV Vaccine. Pediatrics (2015) 0.94
Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions. Eur J Cancer (2015) 0.93
Immune responses elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in previously vaccinated adult women. Vaccine (2012) 0.93
Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses. PLoS One (2013) 0.92
Immunocytochemical characterization of large granular lymphocytes in normal cervix and HPV associated disease. J Pathol (1991) 0.91
Characteristics of memory B cells elicited by a highly efficacious HPV vaccine in subjects with no pre-existing immunity. PLoS Pathog (2014) 0.91
A comparative trial of standard or high-dose S subunit recombinant hepatitis B vaccine versus a vaccine containing S subunit, pre-S1, and pre-S2 particles for revaccination of healthy adult nonresponders. J Infect Dis (1997) 0.90
Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths. Vaccine (2013) 0.90
Long-term immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in 10- to 14-year-old girls: open 6-year follow-up of an initial observer-blinded, randomized trial. Pediatr Infect Dis J (2014) 0.88
The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population. Vaccine (2002) 0.88
Prevention of hepatitis B virus infection and liver cancer. Recent Results Cancer Res (2014) 0.87
Specific HLA class I down-regulation is an early event in cervical dysplasia associated with clinical progression. Lancet (1998) 0.86
Host responses to infection with human papillomavirus. Curr Probl Dermatol (2014) 0.86
Immunoprevention of human papillomavirus-associated malignancies. Cancer Prev Res (Phila) (2014) 0.84
A Single Human Papillomavirus Vaccine Dose Improves B Cell Memory in Previously Infected Subjects. EBioMedicine (2016) 0.82
Long-term Effects of Hepatitis B Immunization of Infants in Preventing Liver Cancer. Gastroenterology (2016) 0.80
Intraepithelial macrophage infiltration is related to a high number of regulatory T cells and promotes a progressive course of HPV-induced vulvar neoplasia. Int J Cancer (2014) 0.80
Treatment failure in patients with HPV 16-induced vulvar intraepithelial neoplasia: understanding different clinical responses to immunotherapy. Expert Rev Vaccines (2012) 0.77
Cervical screening in the 21st century. J Med Assoc Thai (2004) 0.76
Prevention of hepatitis B virus infection: from the past to the future. Eur J Clin Microbiol Infect Dis (2015) 0.75